Tavist Sinus, available in August, is first Novartis product launch.
• By The Tan Sheet
NOVARTIS TAVIST SINUS TO HIT SHELVES IN AUGUST as the first offspring of the December 1996 marriage of Ciba and Sandoz. Unlike older siblings Tavist-1 and Tavist-D, Tavist Sinus does not contain clemastine fumarate. Each Tavist Sinus tablet contains 500 mg acetaminophen and 30 mg pseudoephedrine HCl, a familiar monograph combination available in a number of currently marketed OTCs, including McNeil's Sine-Aid and Warner Wellcome's Sinutab.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.
Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.